Login to Your Account



$34M Up Front; $440M Total

HCV Frenzy Continues: Novartis Licenses Enanta NS5A Inhibitor

By Trista Morrison
Staff Writer

Tuesday, February 21, 2012

Continuing the recent frenzy of dealmaking activity in the hepatitis C virus (HCV) space, Enanta Pharmaceuticals Inc. is expected to announce Tuesday morning that it licensed preclinical NS5A inhibitor EDP-239 to Novartis AG in a deal worth up to $440 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription